China (Mainland)
Premiumsupplier 
MDL 29951 CAS NO.130798-51-5
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- MDL 29951
- 2-Carboxy-4,6-dichloro-1H-indole-3-propionic acid;3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid;2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid;MDL-29951 2-Carboxy-4,6-dichloro-1H-indo
- 130798-51-5
Quick Details
- ProName: MDL 29951
- CasNo: 130798-51-5
- Molecular Formula: C12H9Cl2NO4
- Appearance: off white powder
- Application: CAS：130798-51-5； Small molecule inhib...
- DeliveryTime: 2 months
- PackAge: 100g,500g,1kg,25kg
- Port: shang hai
- ProductionCapacity: 1000 Gram/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
IC50 value: 0.14 mM ([3H]glycine binding) [1].
Target: NMDA receptor
in vitro: MDL-29951 was approximately 2000-fold selective for the glycine binding site relative to the glutamate recognition sites. MDL-29951 completely inhibited the use-dependent binding of [3H]N-[1-(2-thienyl) cyclohexyl]-piperidine and was noncompetitive, glycine-reversible inhibitor of both NMDA-induced biochemical and electrophysiological responses in brain slice preparations [1]. MDL-29951, an antagonist of the glycine site of the NMDA receptor, has been found to be an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase [2]. MDL29951 did not activate any of the known uracil or adenine nucleotide-activated P2Y receptors or cysteinyl leukotriene receptors [3].
in vivo: MDL-29951 produced parallel rightward shifts in the glycine requirement for demonstration of NMDA-stimulated elevations in cytosolic calcium in cultured neuronal preparations. The glycine antagonists were potent anticonvulsants after their i.c.v. administration to audiogenic seizure-susceptible DBA/2J mice[1]. MDL29951 diminished myelination in primary oligodendrocytes isolated from heterozygous mice but had no effect on myelination in oligodendrocytes from GPR17 knockout mice [3].